Swiss pharmaceutical company Novartis has filed a lawsuit against President Joe Biden's administration over a disagreement regarding the 340B Drug Discount Program. The company claims that the U.S. Health Resources and Services Administration interpreted a federal law wrongly, preventing Novartis from changing payment terms for participating hospitals. This move by Novartis could have significant repercussions on the negotiation process for the company's popular heart drug, Entresto, and its pricing under Medicare. Stay updated on market-moving news with TheFly and check out top-performing stocks on TipRanks.
Novartis Sues Biden Administration Over 340B Drug Discount Program
Swiss pharmaceutical giant Novartis has filed a lawsuit against the Biden administration over a disagreement regarding the 340B Drug Discount Program. The company claims that the U.S. Health Resources and Services Administration (HRSA) interpreted a federal law wrongly, preventing Novartis from changing payment terms for participating hospitals.
The 340B Drug Discount Program is a federal program that was established in 1992 to provide discounted prescription drugs to low-income and uninsured patients. Hospitals that participate in the program are required to pass along the discounts they receive from drug manufacturers to patients.
Novartis argues that the HRSA has misinterpreted the 340B law by requiring drug manufacturers to provide discounts to hospitals regardless of whether the drugs are actually used to treat low-income or uninsured patients. The company says that this interpretation of the law has led to "significant overpayments" to hospitals and that it has been forced to subsidize the program with its own profits.
The lawsuit could have significant repercussions on the negotiation process for Novartis's popular heart drug, Entresto. The drug is currently covered under Medicare Part D, and Novartis is seeking to change the payment terms for Entresto in order to increase its profits. The lawsuit could delay or prevent Novartis from making these changes, which could impact the price of Entresto for Medicare beneficiaries.
Background
The 340B Drug Discount Program was created as part of the Omnibus Budget Reconciliation Act of 1990. The program was originally designed to help hospitals that serve a disproportionate share of low-income and uninsured patients. The program has since been expanded to include a wider range of hospitals, including many that do not serve a disproportionate share of low-income and uninsured patients.
In 2010, the Affordable Care Act made significant changes to the 340B program. The changes included adding new eligibility requirements for hospitals and increasing the discounts that drug manufacturers are required to provide.
Top 5 FAQs
1. What is the 340B Drug Discount Program?
The 340B Drug Discount Program is a federal program that requires drug manufacturers to provide discounts to hospitals that serve a disproportionate share of low-income and uninsured patients. The program is designed to help these hospitals provide affordable prescription drugs to their patients.
2. What is Novartis's lawsuit about?
Novartis is suing the Biden administration over the HRSA's interpretation of the 340B law. Novartis argues that the HRSA is requiring drug manufacturers to provide discounts to hospitals regardless of whether the drugs are actually used to treat low-income or uninsured patients.
3. What could the lawsuit mean for Novartis?
The lawsuit could delay or prevent Novartis from making changes to the payment terms for its popular heart drug, Entresto. This could impact the price of Entresto for Medicare beneficiaries.
4. What could the lawsuit mean for the 340B program?
The lawsuit could have a significant impact on the 340B program. If Novartis is successful in its lawsuit, it could lead to changes in the way that the program is administered. This could make it more difficult for hospitals to participate in the program or could reduce the discounts that hospitals receive from drug manufacturers.
5. What is the future of the 340B program?
The future of the 340B program is uncertain. The program has been the subject of ongoing debate, with some stakeholders arguing that it is too costly and that it does not effectively target low-income and uninsured patients. However, the program remains popular with hospitals and patient advocates, and it is likely to continue to be a source of controversy in the years to come.
The Indian stock market started the day on a negative note, with the Sensex and Nifty both opening in the red. This was due to weak global cues, with the BSE Sensex shedding 160.86 points and the Nifty falling 75.9 points in early trading. However, some stocks showed positive performance, with Eternal leading the pack. Meanwhile, Nifty 50's early indicator Gift Nifty indicated a positive start for the day. The previous day, Foreign Institutional Investors were net sellers while Domestic Institutional Investors bought equities.
The Telangana Southern Power Distribution Company Limited (TGSPDCL) has introduced "Currentolla Praja Baata" in Nalgonda, Medak, Mahabubnagar, Ranga Reddy, and Hyderabad, aimed at enhancing power distribution in the region. Led by CMD Musharraf Faruqui, the initiative will involve over 9,500 employees who will personally visit different areas to interact with consumers and address complaints. This program hopes to minimize power losses, strengthen the network, and improve the quality and reliability of power supply in Telangana.
A new Randstad India report reveals insights about India's youngest workforce cohort and their expectations for their careers. Gen Z prioritizes financial security, flexibility, and a sense of purpose in their job, requiring employers to go beyond just providing a decent salary. With a preference for a combination of a full-time job and a side hustle, Gen Z's mobility is driven by the pursuit of growth, making it crucial for employers to invest in continuous learning and foster inclusive cultures to retain this transformative generation.
According to Randstad India's latest report, young professionals in India are redefining workplace norms by prioritizing factors like pay, flexibility, and personal values. The report also reveals that Gen Z values continuous learning through AI tools and is more concerned about the impact of AI on job security. This calls for businesses to adapt to changing preferences and attract the next generation of talent by offering a mix of technical excellence and personal autonomy. The findings also emphasize the need for inclusive cultures and flexible policies in order to build resilient, future-ready businesses.
With the Gen-Z workforce making up about 27% of India's population, companies are struggling to retain this energetic cohort. A recent report by Randstad highlights the need for a change in mindset from employers towards the Gen-Zs. While they have long-term aspirations, they are also quick to move on to new opportunities if they feel undervalued or underpaid. This poses a challenge for employers who must find ways to keep this ambitious and driven generation engaged and progressing within their organizations.
Union Home Minister and Minister of Cooperation, Amit Shah, congratulated Amul and Indian Farmers Fertiliser Cooperative Limited (IFFCO) for securing the first and second ranks in the global ranking for cooperatives. This achievement is a testament to the boundless potential of cooperatives, which are being transformed into a global model of empowerment and self-reliance by Prime Minister Narendra Modi. The dairy sector, which is the backbone of rural livelihoods in India, has combined farmer-led cooperatives, women's participation and scientific practices to achieve remarkable progress. Additionally, the National Co-operative Exports Limited, set up by the government, has achieved a significant milestone in exporting agricultural commodities.
After purchasing his retirement property in Swansea, David Barlow has been forced to live in a motorhome on his driveway due to persistent damp and mould issues. Despite complaints to his property managers, the issue has not been resolved and Barlow fears for his belongings. The problem is believed to have been caused by faulty insulation installed by British Gas, but the company denies responsibility. This situation has put a hold on Barlow's retirement plans and has left him feeling frustrated and stuck.
US-based private equity firm Tillman Global Holdings (TGH) is reportedly in advanced discussions to invest up to $6 billion in Vodafone Idea Ltd, which could lead to a change in operational control. However, the investment is contingent on the Indian government providing comprehensive relief covering AGR and spectrum payment dues. If the deal goes through, it could dilute existing promoter holdings, including those held by Aditya Birla Group and Vodafone Plc. While the news has boosted investor sentiment, analysts caution that government approval and debt restructuring clarity are key to the execution of the deal.
The Indian real estate market is undergoing a major shift with rising home prices, as apartments priced between Rs 2 crore and Rs 5 crore now dominate sales. This change has been highlighted by a Redditor who expressed concerns over the dwindling chances of middle-class buyers to afford a house. According to a Moneycontrol report, the trend is a result of big developers focusing more on luxury projects, leaving affordable housing in the backseat. As a result, home ownership for the middle-class seems like a distant dream, with even government employees struggling to afford these expensive properties.
Vodafone Idea's share price saw a significant increase of 14% after the Supreme Court provided further clarity on the AGR dues issue. The court clarified that the government can consider providing relief for both additional and reassessed AGR dues, giving some respite to the struggling telecom operator. At the time of writing, Vodafone Idea's share price was trading at Rs 9.51, with a gain of 8.93%. This comes after the court's previous hearing which did not provide a clear ruling on whether the relief applies to only Vodafone Idea's plea or the entire pending AGR amount of nearly Rs 80,000 crore.